12月24日 - ** 制药商Agios Pharmaceuticals AGIO.O股价盘前上涨8.6%至26.70美元
** 该公司周二晚些时候表示，美国食品和药物管理局已批准扩大其药物的使用范围，用于治疗一种血液疾病。
** 该药名为 mitapivat，品牌名称为 Aqvesme，目前正在接受测试，用于治疗α-或β-地中海贫血症成人患者的贫血症。
** 这种遗传性疾病会影响人体产生血红蛋白和健康红细胞的能力
** Mitapivat 于 2022 年获得美国 FDA 批准，用于治疗丙酮酸激酶缺乏症成人患者的低红细胞计数，品牌名称为 Pyrukynd。
** 截至上次收盘，股价累计下跌 25.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.